|
|
“Growing numbers
of specific and costly treatment options with relatively low response
rates have created a need for diagnostic tools that aid in correct therapeutic
selection and monitoring of treatment response”
– Genetic Engineering News |
 |
|
|
- Enlyton is presently validating a proprietary cancer-specific tracer for use in improving the cancer detection capability of Positron Emission Tomography (PET) and Computed Tomography (CT). Initial experimentation has demonstrated the advantages of ATA-1 for use in PET/CT.
- In parallel, Enlyton has conducted feasibility studies that demonstrate the promise of its first non-radioisotope-labeled molecular target candidate for proposed use in real-time, surgical cancer detection.
- From a licensed family of molecular targets, Enlyton is validating other molecular targets and techniques that address imaging and detection applications for adenocarcinoma and other cancers.
|